Pharma giant Novo Nordisk announced that it is collaborating with WeightWatchers to offer Wegovy through NovoCare Pharmacy, effective July 1. Through the partnership, WeightWatchers’ telehealth program, integrated into NovoCare Pharmacy, will enable new uninsured or…
Continue Reading
Gretchen Zimmermann, MBA, RD, VP of Clinical Strategy at Vida Health
The false belief that people with obesity do not have eating disorders is one of the most harmful misconceptions in obesity care. In reality,…
Continue Reading
What You Should Know:
– LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).
– The comprehensive package includes both the GLP-1 medication…
Continue Reading
Patent Monopolies Drive Record Profits
Novo Nordisk and Eli Lilly have transformed GLP-1 receptor agonists into unprecedented profit machines. These blockbuster drugs, approved for diabetes and weight loss, generate billions while leaving many patients unable…
What You Should Know:
– Veradigm, a provider of healthcare data and technology solutions, today announced a significant advancement in the application of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for…
Continue Reading
Source: MyPhenome genetic obesity test
What You Should Know:
– Phenomix Sciences (Phenomix), a commercial precision obesity medicine biotechnology company, today announced the initiation of its first prospective, placebo-controlled clinical study.
– The research will evaluate…
Continue Reading
Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients.
Compounded GLP-1s are custom-made by compounding pharmacies and include the same…
Continue Reading
Understanding the Eye Risk Concerns
Recent findings have raised alarming concerns about potential ophthalmic complications associated with popular diabetes medications semaglutide and tirzepatide. These incretin-based therapies, while highly effective for managing type 2 diabetes and…
What You Should Know:
– Helix, a leader in population genomics and precision health, today announced the launch of a new clinico-genomic dataset comprising over 15,000 patients treated with glucagon-like peptide-1 (GLP-1) agonists.
– These medications,…
Continue Reading
Women’s telehealth company Wisp announced a strategic partnership with food as medicine platform Nourish to allow Wisp patients to access nutrition counseling services via their health insurance or an exclusive self-pay rate The aim is…
Continue Reading
